Emerging platinum(IV) prodrug nanotherapeutics: A new epoch for platinum-based cancer therapy

• Published in: Journal of Controlled Release Vol. 361; pp. 819 - 846
• Main Authors: Zheng, Shunzhe, Li, Guanting, Shi, Jianbin, Liu, Xinying, Li, Meng, He, Zhonggui, Tian, Chutong, Kamei, Ken-ichiro
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.09.2023; Elsevier BV
• Subjects: antineoplastic agents; Cancer therapy; Combination therapy; Combined Modality Therapy; cytotoxicity; DNA; dose response; Drug Delivery Systems; drug resistance; drug therapy; Humans; Medical Oncology; Neoplasms; Platinum; Platinum drug; Platinum(IV) prodrug; Prodrug nanotherapeutics; Prodrugs; Platinum(IV) prodrug; Prodrug nanotherapeutics; Combination therapy; Platinum drug; Cancer therapy

Owing to the unique DNA damaging cytotoxicity, platinum (Pt)-based chemotherapy has long been the first-line choice for clinical oncology. Unfortunately, Pt drugs are restricted by the severe dose-dependent toxicity and drug resistance. Correspondingly, Pt(IV) prodrugs are developed with the aim to...